On an April afternoon in 2009, in his home office near Austin, Texas, John Bird was hunched over his computer trying to figure out if a Chinese company some 6,500 miles away was anything close to what it claimed to be.
Regeneron Pharmaceuticals Inc. reported a successful study result in its new drug for treating gout, the first of three new treatments that may generate at least $2 billion a year in revenue.
Glu Mobile Inc., the maker of “Contract Killer: Zombies” and “Gun Bros” games for smartphones, is offering potential buyers the fastest sales growth among U.S. mobile gaming competitors.
Skullcandy Inc., the headphone maker known for colorful designs, is turning into a takeover target after falling more than almost every other initial public offering during the past 18 months.
Now that Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
ICU Medical Inc., the maker of intravenous medical equipment that surged to a record this week after Bloomberg News said it’s considering a sale, could fetch 21 percent more in a takeover.